DVM Newsletter reported earlier this week that a Seattle company is working on the development of a “pot patch” for pain control in dogs, cats and horses that could be rolled out to the market by the end of the year.

Rachael Whitcomb reports “while it’s reported that medical marijuana use in people has gained in popularity in last few years, a veterinary pain management expert says transdermal use of marijuana could have a place in a veterinarian’s armamentarium.”

“It actually really could be beneficial if it’s something that is well developed,” says Dr. Lisa Moses, VMD, Dipl. ACVIM. Moses serves on the board of directors for the International Veterinary Academy of Pain Management (IVAPM) and leads the pain management service at Angell Animal Medical Center in Boston. “The problem with a lot of stuff is that we know there’s a lot of things that should work, but because of manufacturing sloppiness or poor regulation on a supplement, we don’t know if our patients are getting what we think they’re getting.”

The patent rights for the marijuana patch were obtained in February by Medical Marijuana Delivery Systems (MMDS) of Seattle. The product will be marketed under the name Tetracan, according to the company, for transcutaneous delivery of medical marijuana to humans and animals.

“Tetracan will become the dominant identity for medical marijuana across the United States and throughout the world,” says MMDS spokesperson Jim Alekson. “The industry needs to shed the word ‘marijuana,’ and focus on the holistic, therapeutic pain relief benefits of topical applications.”